Disproportionality analysis of satralizumab in FDA adverse event reporting system and Japanese adverse drug event report: a pharmacovigilance study

BackgroundTo date, no post-marketing safety studies of satralizumab have been conducted. This study aims to evaluate the post-marketing safety profile of satralizumab using data from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Re...

Cijeli opis

Bibliografski detalji

Glavni autori:	Linhai Zhang, Rong Yan, Zucai Xu
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-01-01
Serija:	Frontiers in Immunology
Teme:	FAERS adverse events NMOSD satralizumab pharmacoepidemiology
Online pristup:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1647306/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!